Spanish Health Spending To Rise in 1995

2 October 1994

Health care spending in Spain is set to increase by more than 200 billion pesetas ($1.5 billion) in 1995. Half of the rise is being attributed to the new financing system for public health care (Marketletters passim) which was agreed towards the end of September by central government and the autonomous communities. The latter are now responsible for over 50% of health care expenditure, according to the Spanish financial daily, Cinco Dias.

The object of the agreement is to establish the real cost of services, so that health service managers can see clearly the margin for maneuver which they have. It is hoped that this will help avoid the high levels of overspending that have occurred in the last few years.

Accumulated debts arising from health care provision in Spain during 1992 and 1993 amounted to 370 billion pesetas ($2.8 billion), and it is estimated that it will take until 1996 to clear this debt. For the current year, the Ministry for the Economy has set aside 95 billion pesetas ($760.3 million), which will go towards clearing the debt.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight